Summary
Dabrafenib has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cervical Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cervical Cancer. ClinicalTrials.gov lists 8 registered trials linking Dabrafenib to Cervical Cancer: 4 are active or not yet recruiting; 1 has completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07010393). It plans or enrolled 335 participants. Registration activity spans 2012 to 2025. No published literature item is linked to Dabrafenib and Cervical Cancer in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Cervical Cancer ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: CIN2/3 (precancerous): spontaneous regression in 40-60% of CIN2 without treatment; CIN3: regression in ~30%; invasive cervical cancer: no spontaneous regression.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 45.0 (trials 25.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 4 active / not yet recruiting, 1 completed, 3 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor; inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | BRAF |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07010393 | Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study 2025 | not yet recruiting | Phase 4 | 335 |
| NCT04238624 | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer 2020 | active, not recruiting | Phase 2 | 16 |
| NCT04544111 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer 2020 | active, not recruiting | Phase 2 | 19 |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer 2012 | completed | Phase 2 | 53 |
| NCT05182931 | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) 2022 | status unknown | Phase 2 | 80 |
| NCT04619316 | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition 2018 | status unknown | Phase 2 | 70 |
| NCT04554680 | Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy 2020 | status unknown | Phase 2 | 5 |
| NCT01947023 | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery 2013 | active, not recruiting | Phase 1 | 23 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: inhibitor; inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRAF. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Dabrafenib approved for Cervical Cancer?
Dabrafenib has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cervical Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cervical Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Dabrafenib in clinical trials for Cervical Cancer?
ClinicalTrials.gov lists 8 registered trials linking Dabrafenib to Cervical Cancer: 4 are active or not yet recruiting; 1 has completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07010393). It plans or enrolled 335 participants. Registration activity spans 2012 to 2025.
What does the evidence show for Dabrafenib in Cervical Cancer?
Dabrafenib has 1 completed registered trial for Cervical Cancer but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRAF. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.